Navigation Links
Simple home spit test to spot deadly pre-eclampsia

A simple spit test designed to detect pre-eclampsia in the early stages is being trialed in a UK hospital, reports Cath O'Driscoll in Chemistry & Industry, the magazine of the SCI. The test, which is designed to be used at home, will allow mums-to-be to check for themselves whether they are at risk of the condition, which can be symptomless in the early stages but kills 1000 babies in the UK every year. The test is expected to be more reliable than the traditional blood pressure and urine tests conducted in GPs' offices and hospitals.

Pre-eclampsia is also a leading cause of maternal mortality, killing one woman globally every six seconds, according to the UK's Action on Pre-eclampsia (APEC). Earlier detection and intervention could save lives.

Standard blood pressure and urine tests are unreliable, and there is a lot of scope for "user error", according to Michael Rich, chief executive of APEC. In addition, high blood pressure can be caused by a variety of factors other than pre-eclampsia, and even when a woman develops pre-eclampsia, problems with high blood pressure may not occur until the latter stages.

The new test works by monitoring levels of urate, a salt of uric acid, increased levels of which are thought to be due to impaired kidney excretion in pre-eclampsia.

'A salivary urate test is simple, non-invasive, quick and cheap and can be done at any time. As a metabolic test independent of blood pressure, it may obviate the need for hospital admission,' said retired hospital rheumatologist Brian Owen-Smith, who invented the test.

The trial, which will eventually involve 1000 women, is underway at St Richards Hospital in Chichester. Trial subjects send away saliva-wiped swabs for analysis. Results are expected early next year. The ultimate aim is to develop a "traffic light" detection kit for use in the home.

Pre-eclampsia is thought to be the result of problems relating to the implantation of the p lacenta. The main diagnostic symptoms are raised blood pressure and the excretion of protein in the urine. While there is no cure, other than the delivery of the baby and removal of the faulty placenta, early detection and management of the problem can have a big impact on patient outcome.


'"/>

Source:Society of Chemical Industry


Related biology news :

1. Simple drug has the potential to save many lives threatened by malaria
2. Discovery Promises Simpler Therapy for Sickle Cell Disease
3. Simple sea sponge helps scientists understand tissue rejection
4. Simple explanation for complex pattern of feather development
5. Simple idea to dramatically improve dengue vaccinations
6. Genome of deadly amoeba shows surprising complexity, evidence of lateral gene transfer
7. Scientists seek answers on what activates deadly anthrax spores
8. U of M researcher examines newly emerging deadly disease
9. Smart drug targets deadly brain cancer
10. Shark attack worries? Driving to the beach is more deadly
11. Unusual antibiotics show promise against deadly superbugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... WHIPPANY, N.J. , May 4, 2016 /PRNewswire/ ... evaluating its oncology compound Stivarga ® (regorafenib) ... hepatocellular carcinoma (HCC) has met its primary endpoint ... The study, called RESORCE, evaluated the efficacy and ... disease has progressed after treatment with sorafenib. The ...
(Date:5/4/2016)... May 4, 2016 According to ... "Metabolomics Market - Global Industry Analysis, Size, Share, Growth, ... is anticipated to expand at a CAGR of 17.1% ... by 2024. Metabolomics is the extensive study ... biofluids, tissues or organisms. Together, these small molecules and ...
(Date:5/4/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... leveraged recent innovations in biotechnology to help treat hormonal and stress related hair ... Nutrafol® has captured the hearts of key opinion leaders in the medical and ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... development, skill-building and compliance training platform on mobile devices, today released a new ... Regulatory Requirements for Medical Devices. The course is essential for owners or operators ...
Breaking Biology Technology: